Lincoln Pharmaceuticals Ltd
LINCOLNLincoln Pharmaceuticals Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the P/E sits at the 73rd percentile of its own range — the multiple has already done part of the work.
The price is in a confirmed uptrend (18 weeks in) while the P/E sits at the 73rd percentile of its own 10-year range. Underneath, the last four quarters read mixed — profit +0.0% year on year, and 100% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Lincoln Pharmaceuticals Ltd trades at ₹597, in a confirmed uptrend and 18 weeks into that stage. That is +0.6% against its own 200-day average. It sits at 51% of a 52-week range of ₹453 to ₹734. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (4 weeks and counting).
Today the stock is in a confirmed uptrend — week 18 of stage 2, confirmed. At ₹597 it trades +0.6% versus its 200-day average and sits at 51% of its 52-week range (₹453–₹734).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +304% while the NIFTY 500 moved +280% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (4 weeks and counting; last ahead the week of 2026-06-25) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 73rd percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Lincoln Pharmaceuticals Ltd trades at 13.2× P/E, at the pricey end of its own range (73rd percentile). Its long-run median P/E is 11.2×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 13.2× is at the pricey end of its own range (73rd percentile), against a long-run median of 11.2× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +6.7% against a +6.7% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the +10.1%/yr price move, ~+7.2%/yr came from earnings growth and ~+2.9 pp from the multiple (expanding); over 10y, of the +13.4%/yr price move, ~+9.7%/yr came from earnings growth and ~+3.7 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Lincoln Pharmaceuticals Ltd reads as turning around on its fundamental arc. Turning around — profit growth swung from −25.0% at the trough to +0.0% off a 4-quarter-old trough (single-quarter readings), ROCE slipping at 16.0%. The read is built from 10 quarters across 3 curves, on partial evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +7.7% | +9.6% | +9.6% | +5.3% |
| Profit | +7.3% | +6.4% | +7.3% | +13.9% |
| EPS | +6.7% | +6.4% | +7.1% | +11.7% |
| Share price | +6.7% | +14.2% | +10.1% | +13.4% |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
43.6/100 — rank 25 of 43 in Pharma - Formulators · 83% evidence confidence
Lincoln Pharmaceuticals Ltd scores 43.6 out of 100 against the 43 companies it is compared with in Pharma - Formulators, ranking 25. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 12.1 + 16 + 9.8 + 5.7 = 43.6. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Lincoln Pharmaceuticals Ltd reported ₹187 Cr of revenue in the Mar 26 quarter, +11.3% year on year. That is the 10th straight quarter of year-on-year growth. Over 10 years it has compounded at 5.3% a year. The last full year, FY26, came in at ₹671 Cr. The last four reported quarters add to ₹670 Cr.
Lincoln Pharmaceuticals Ltd reported ₹187 Cr of revenue in the Mar 26 quarter, +11.3% year on year. That is the 10th straight quarter of year-on-year growth. Over 10 years it has compounded at 5.3% a year. The last full year, FY26, came in at ₹671 Cr. The last four reported quarters add to ₹670 Cr.
FY26 revenue came in at ₹671 Cr (+7.7% on the year), capping 10 years at 5.3% compound. The latest quarter (Mar 26) printed ₹187 Cr, +11.3% year on year — the 10th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +7.5% growth against the decade's 5.3% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +7.5% over the last 4 quarters against +7.5%/yr over the last 8 — stabilising; TTM profit +7.2% vs −2.7%/yr — accelerating.
→ Revenue grew — did margins hold as it scaled? Next: 13.0% this quarter (−3.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Lincoln Pharmaceuticals Ltd's operating margin is 13.0% in the Mar 26 quarter, −3.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 10.0% to 21.0%. The current quarter sits inside that band.
Lincoln Pharmaceuticals Ltd's operating margin is 13.0% in the Mar 26 quarter, −3.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 10.0% to 21.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 13.0%, −3.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 10.0%–21.0%.
🚨 Why the margin moved: operating margin went −2.6 pp year on year while gross margin went +0.1 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
→ Margins slipped — did that reach the bottom line? Next: profit +0.0% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Lincoln Pharmaceuticals Ltd earned ₹12.0 Cr of net profit in the Mar 26 quarter, +0.0% year on year. Full-year FY26 profit was ₹88.0 Cr. The 10-year compound rate is 13.9%. That is 6.4% of the quarter's revenue. The same quarter a year earlier earned ₹12.0 Cr.
Lincoln Pharmaceuticals Ltd earned ₹12.0 Cr of net profit in the Mar 26 quarter, +0.0% year on year. Full-year FY26 profit was ₹88.0 Cr. The 10-year compound rate is 13.9%. That is 6.4% of the quarter's revenue. The same quarter a year earlier earned ₹12.0 Cr.
Mar 26 profit was ₹12.0 Cr, +0.0% year on year. On the full year, FY26 printed ₹88.0 Cr (+7.3%), and the 10-year compound rate is 13.9%.
🚨 Why profit moved: revenue contributed +11.3% and the margin −3.0 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit +7.9% vs revenue +7.5%. Profit and revenue are moving roughly in step.
→ Profit rose — but did the cash follow? Next: 100% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 100% of Lincoln Pharmaceuticals Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹106 Cr of operating cash against ₹88.0 Cr of profit. After ₹24.0 Cr of capital spending, ₹82.0 Cr was left as free cash.
FY26: operating cash of ₹106 Cr against reported profit of ₹88.0 Cr, leaving free cash of ₹82.0 Cr after ₹24.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 100% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 100%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.
Router verdict: the bigger cash user is investment — capital spending ran 2.0× depreciation over three years, so the next section's job is to check what that build-out is buying.
→ So follow the cash to where it goes. Next: ₹76.0 Cr of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Lincoln Pharmaceuticals Ltd's cash conversion cycle runs 82 days in FY26, up from 78 days in FY21. Capital spending ran ₹76.0 Cr over the last 3 years. At FY26 sales of ₹671 Cr each day of that cycle holds about ₹1.8 Cr, so roughly ₹151 Cr sits inside the business at any moment.
FY26: debtors at 88 days, inventory at 94 days — roughly 3.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 82 days, looser than FY21's 78.
The full loop: cash goes out to suppliers and production on day 0; stock waits 94 days to sell; customers pay about 88 days after that; and suppliers themselves are paid at 100 days — netting out to the 82-day cycle.
In money terms: at FY26 sales of ₹671 Cr, each day of the cycle holds about ₹1.8 Cr — so the 82-day loop keeps roughly ₹151 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹76.0 Cr over the last 3 fiscal years against ₹38.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹5.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 16% and the ROIC − WACC spread is +0.6 pp.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Lincoln Pharmaceuticals Ltd earns a ROCE of 16% in FY26. That is up from a trough of 11% in FY14. Return on invested capital clears the cost of that capital by +0.6 percentage points, so growth here adds value rather than only size. The wiring behind it is 13.1% net margin on 0.75× asset turns.
FY26 ROCE is 16%, recovered from a FY14 trough of 11% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 13.1% net margin × 0.75× asset turns × 1.17× balance-sheet leverage ≈ 11.5% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 12.6% − 12.0% = a +0.6 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.01.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Lincoln Pharmaceuticals Ltd carries total debt of ₹4.0 Cr against shareholder equity of ₹758 Cr as of Mar 26, a debt-to-equity of 0.01 — effectively unlevered. On the annual view that ratio went from 0.00 in FY22 to 0.01 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹4.0 Cr against shareholder equity of ₹758 Cr — a debt-to-equity of 0.01. On the annual view, debt-to-equity went from 0.00 (FY22) to 0.01 (FY26). The returns on this page are earned, not borrowed.
→ Who owns this, and are they adding or leaving? Next: the register is quiet.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Lincoln Pharmaceuticals Ltd moved a full percentage point over the last two years — the register is quiet. Domestic institutions moved +0.2 points over the same window, to 0.3%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: +0.6 points over 8 quarters to 4.6%; Domestic institutions: +0.2 points over 8 quarters to 0.3%; Promoters: +0.0 points over 8 quarters to 49.8%.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Lincoln Pharmaceuticals Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Lincoln Pharmaceuticals Ltd this page | 13.2× | ₹1,162 Cr | Turning around | |||
| Sun Pharmaceutical Industries Ltd | 37.5× | ₹4.7L Cr | Improving | |||
| Torrent Pharmaceuticals Ltd | 86.1× | ₹1.9L Cr | Consistent | |||
| Cipla Ltd | 31.8× | ₹1.1L Cr | Deteriorating | |||
| Zydus Lifesciences Ltd | 20.4× | ₹1.1L Cr | Consistent | |||
| Lupin Ltd | 19.1× | ₹1.1L Cr | Consistent | |||
| Mankind Pharma Ltd | 51.4× | ₹1L Cr | Turning around | |||
| Dr Reddys Laboratories Ltd | 29.8× | ₹96,130 Cr | Deteriorating | |||
| Aurobindo Pharma Ltd | 25.1× | ₹88,979 Cr | Mixed | |||
| Biocon Ltd | 182.0× | ₹70,672 Cr | Deteriorating | |||
| Alkem Laboratories Ltd | 27.6× | ₹67,357 Cr | Mixed | |||
| Glenmark Pharmaceuticals Ltd | 21.0× | ₹61,858 Cr | No read | |||
| Ipca Laboratories Ltd | 37.9× | ₹44,720 Cr | Consistent | |||
| Ajanta Pharma Ltd | 37.3× | ₹42,097 Cr | Consistent | |||
| J B Chemicals & Pharmaceuticals Ltd | 53.8× | ₹38,677 Cr | Topping out | |||
| Emcure Pharmaceuticals Ltd | 37.7× | ₹35,679 Cr | Mixed | |||
| Wockhardt Ltd | 106.0× | ₹30,048 Cr | No read | |||
| Rubicon Research Ltd | 102.0× | ₹25,141 Cr | No read | |||
| ERIS Lifesciences Ltd | 30.7× | ₹19,409 Cr | Turning around | |||
| Caplin Point Laboratories Ltd | 29.2× | ₹18,753 Cr | Consistent | |||
| Natco Pharma Ltd | 11.6× | ₹16,504 Cr | Topping out | |||
| Alembic Pharmaceuticals Ltd | 21.4× | ₹15,678 Cr | Turning around | |||
| Corona Remedies Ltd | 64.7× | ₹12,923 Cr | No read | |||
| Marksans Pharma Ltd | 26.7× | ₹11,161 Cr | Consistent | |||
| Akums Drugs & Pharmaceuticals Ltd | 40.3× | ₹10,818 Cr | No read | |||
| Strides Pharma Science Ltd | 16.6× | ₹9,402 Cr | No read | |||
| Suven Life Sciences Ltd | — | ₹8,929 Cr | No read | |||
| FDC Ltd | 22.6× | ₹6,723 Cr | Turning around | |||
| Bliss GVS Pharma Ltd | 37.4× | ₹4,927 Cr | Turning around | |||
| RPG Life Sciences Ltd | 44.3× | ₹4,858 Cr | — | — | — | — |
| Gufic BioSciences Ltd | 59.2× | ₹3,799 Cr | No read | |||
| Kwality Pharmaceuticals Ltd | 42.5× | ₹2,886 Cr | Consistent | |||
| Kwality Pharmaceuticals Ltd | 36.6× | ₹2,483 Cr | Consistent | |||
| Sai Parenterals Ltd | 166.0× | ₹2,366 Cr | — | — | — | — |
| Indoco Remedies Ltd | — | ₹2,247 Cr | No read | |||
| Fredun Pharmaceuticals Ltd | 45.4× | ₹1,480 Cr | — | No read | ||
| Amrutanjan Health Care Ltd | 22.8× | ₹1,472 Cr | Mixed | |||
| Accent Microcell Ltd | 27.1× | ₹1,187 Cr | No read | |||
| Bajaj Healthcare Ltd | 19.3× | ₹1,088 Cr | No read | |||
| Bharat Parenterals Ltd | — | ₹990 Cr | No read |
Frequently asked questions
What is Lincoln Pharmaceuticals Ltd's share price today?
Lincoln Pharmaceuticals Ltd trades at ₹597, +6.7% over the past year. The company is valued at ₹1,162 Cr. The stock sits at 51% of its 52-week range of ₹453–₹734, +0.6% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 18 weeks in. — as of 24 July 2026.
What were Lincoln Pharmaceuticals Ltd's latest quarterly results?
Lincoln Pharmaceuticals Ltd reported revenue of ₹187 Cr and net profit of ₹12.0 Cr for the Mar 26 quarter. Revenue rose 11.3% and profit rose 0.0% year on year. Earnings per share were ₹5.81. The operating margin was 13.0%, 3.0 pp lower than a year earlier. — as of 24 July 2026.
What is Lincoln Pharmaceuticals Ltd's revenue?
Lincoln Pharmaceuticals Ltd reported revenue of ₹187 Cr in the Mar 26 quarter, +11.3% year on year. For the full FY26 fiscal year, revenue was ₹671 Cr (+7.7%). Over the last 10 years revenue compounded at 5.3% a year. — as of 24 July 2026.
What is Lincoln Pharmaceuticals Ltd's profit?
Lincoln Pharmaceuticals Ltd earned ₹12.0 Cr of net profit in the Mar 26 quarter, +0.0% year on year. Full-year FY26 profit was ₹88.0 Cr. The operating margin ran 13.0% in the latest quarter. — as of 24 July 2026.
What is Lincoln Pharmaceuticals Ltd's market cap?
Lincoln Pharmaceuticals Ltd's market capitalisation is ₹1,162 Cr at a share price of ₹597. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Lincoln Pharmaceuticals Ltd's P/E ratio?
Lincoln Pharmaceuticals Ltd trades at a P/E of 13.2×, at the 73rd percentile of its own 10-year range, against a long-run median of 11.2×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Lincoln Pharmaceuticals Ltd pay a dividend?
Yes — Lincoln Pharmaceuticals Ltd's dividend payout was 4% of profit in FY26, and it recorded a payout in each of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is Lincoln Pharmaceuticals Ltd overvalued?
On its own history, Lincoln Pharmaceuticals Ltd looks expensive against its own history: its P/E of 13.2× sits at the 73rd percentile of its 10-year range (long-run median 11.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 24 July 2026.
Is Lincoln Pharmaceuticals Ltd growing?
The picture is mixed for Lincoln Pharmaceuticals Ltd: latest-quarter revenue +11.3% year on year, profit +0.0%, and the margin −3.0 pp at 13.0%. The 10-year compound rates are 5.3% (revenue) and 13.9% (profit). The earnings engine currently reads: mixed — as of 24 July 2026.
How is Lincoln Pharmaceuticals Ltd performing?
Lincoln Pharmaceuticals Ltd is in a confirmed uptrend, 18 weeks in. Its latest quarter's revenue rose 11.3% and profit rose 0.0% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 4 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is Lincoln Pharmaceuticals Ltd in?
Turning around — profit growth swung from −25.0% at the trough to +0.0% off a 4-quarter-old trough (single-quarter readings), ROCE slipping at 16.0%. The read comes from the last 12 quarters of growth (revenue growth +11.3% latest, profit growth +0.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is Lincoln Pharmaceuticals Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 18 of stage 2), trading +0.6% versus its 200-day average and at 51% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Lincoln Pharmaceuticals Ltd beating the market?
Not lately — on a trailing-13-week view Lincoln Pharmaceuticals Ltd is currently behind the NIFTY 500 (4 weeks and counting; last ahead the week of 2026-06-25), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +304% against the NIFTY 500's +280% — ahead of the index over the full window. — as of 24 July 2026.
Will Lincoln Pharmaceuticals Ltd's share price go up?
This page publishes no price forecast for Lincoln Pharmaceuticals Ltd. What it measures instead: the share price is ₹597, the price is in a confirmed uptrend 18 weeks in. Its P/E of 13.2× sits at the 73rd percentile of its own 10-year range. — as of 24 July 2026.
Who owns Lincoln Pharmaceuticals Ltd?
Promoters hold 49.8% of Lincoln Pharmaceuticals Ltd, foreign institutions 4.6%, domestic institutions 0.3% and the public 45.4% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 24 July 2026.
Does Lincoln Pharmaceuticals Ltd have too much debt?
No — Lincoln Pharmaceuticals Ltd's debt-to-equity is 0.01, and operating profit covers the interest bill 98×. FY26 borrowings were ₹4.0 Cr against equity of ₹758 Cr. The returns on this page are earned, not borrowed — as of 24 July 2026.
What is Lincoln Pharmaceuticals Ltd's capex?
Lincoln Pharmaceuticals Ltd spent ₹76.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹24.0 Cr, with ₹5.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Lincoln Pharmaceuticals Ltd's cash flow?
Lincoln Pharmaceuticals Ltd generated ₹106 Cr of operating cash flow in FY26 and ₹82.0 Cr of free cash flow after ₹24.0 Cr of capital spending. Reported profit that year was ₹88.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Lincoln Pharmaceuticals Ltd's profit real cash?
Yes — over the last 3 fiscal years, 100% of Lincoln Pharmaceuticals Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹106 Cr against reported profit of ₹88.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 24 July 2026.
Where is Lincoln Pharmaceuticals Ltd in its business cycle?
Lincoln Pharmaceuticals Ltd's FY26 operating margin was 15.0%, against a 13-year band of 10.0%–21.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 13.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Lincoln Pharmaceuticals Ltd story?
Biggest watch item: the P/E sits at the 73rd percentile of its own range — the multiple has already done part of the work. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Lincoln Pharmaceuticals Ltd a stock worth studying right now?
This is not investment advice. The machine read: Lincoln Pharmaceuticals Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.